Pradaxa (dabigatran etexilate mesylate)

23:22 EST 12th December 2018 | BioPortfolio

Pradaxa® (dabigatran etexilate mesylate) capsules is a prescription blood-thinning medicine used to reduce the risk of stroke and blood clots in people with atrial fibrillation not caused by a heart valve problem. PRADAXA is not for use in people with artificial (prosthetic) heart valves.

Blood clots are a leading cause of AFib-related strokes

For people with atrial fibrillation, or AFib, not caused by a heart valve problem, PRADAXA reduces the risk of a blood clot forming in the heart and traveling to the brain, where it can cause a stroke. A stroke caused by a blood clot is called an ischemic (is-KEE-mic) stroke.

How clots can form

When your heart beats irregularly, it doesn't pump blood as effectively as it should.
This can cause blood to pool in the upper chambers of your heart (called the atria).
This pooling can cause a clot to form in your heart.
A clot in your heart can break away and travel directly to your brain. There, it can block an artery and cause a stroke.

How PRADAXA helps stop clots from forming in your heart

PRADAXA is a type of medicine known as a direct

thrombin inhibitor.
PRADAXA works by attaching itself to thrombin—the blood's central clotting agent. This reduces the ability of the thrombin to form a clot. That is why it is so important that you keep taking PRADAXA exactly as prescribed by your doctor. Stopping PRADAXA increases your risk of having a stroke.
In a clinical trial, PRADAXA was proven superior to warfarin at reducing the risk of stroke in patients with AFib not caused by a heart valve problem.


Quick Search


review and buy Pradaxa (dabigatran etexilate mesylate) market research data and corporate reports here